Trial intelligence / Profile preview

Phase I/II open-label study of D3S-002 in advanced solid tumors with MAPK pathway mutations

CTR20233589Phase 2Active

Sponsor

D3 Bio

Start

Jan 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1